002581 未名医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-1.440-14.929-0.61411.966-8.800
总资产报酬率 ROA (%)-1.286-12.770-0.52110.373-6.661
投入资产回报率 ROIC (%)-1.412-14.132-0.56611.071-7.056

边际利润分析
销售毛利率 (%)80.65280.59678.65778.68680.376
营业利润率 (%)-11.508-68.2559.43067.811-70.679
息税前利润/营业总收入 (%)-11.444-71.1785.60970.558-68.613
净利润/营业总收入 (%)-11.773-74.952-0.24069.203-71.588

收益指标分析
经营活动净收益/利润总额(%)107.99457.758-1,464.805-75.986128.645
价值变动净收益/利润总额(%)-12.733-55.1261,708.919169.396-54.324
营业外收支净额/利润总额(%)-4.0216.352-164.6161.9803.025

偿债能力分析
流动比率 (X)8.6073.7181.4232.1993.704
速动比率 (X)7.6923.0791.2031.9503.361
资产负债率 (%)5.1146.99213.57110.35910.351
带息债务/全部投入资本 (%)0.5010.5667.0926.2205.618
股东权益/带息债务 (%)19,578.28917,332.7481,296.2691,490.2921,643.217
股东权益/负债合计 (%)1,760.6171,265.802612.512837.013837.178
利息保障倍数 (X)30.078-41.7192.74251.213-16.067

营运能力分析
应收账款周转天数 (天)119.087125.947211.052255.369492.859
存货周转天数 (天)362.425356.911340.998283.525455.114